The precarious climate in the US might have spooked some pharma investors – but others are looking to targeted therapies to get more bang ...
The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?
Data generating devices may seem gimmicky, but they are poised to transform healthcare
If pharma is to keep whizzing ahead, it needs to rethink its approach to market access